“…Because dysregulation of STAT signaling is linked with BOT-4-one Inhibited tyrosine phosphorylation of STAT92E and exhibited anticancer activities in Drosophila Schneider cells [27] Methotrexate, aminopterin Inhibited the JAK-STAT pathway in Drosophila [28] FDA-approved drugs Drosophila stem cell tumors were sensitive to a wide range of drugs (gemcitabine, methotrexate, thiotepa, topotecan, rapamycin); paradoxically, a subset of drugs (actinomycin, bortezomib, paclitaxel, vincristine, vinblastine, mitomycin, daunorubicin) that inhibited growth of cancer stem cells also induced hyperproliferation of wild-type stem cells driven by the JAK-STAT pathway [21] ZD6474 Oral dose of the drug suppressed the defects associated with wild-type and oncogenic forms of dRET [31,32]; exhibited efficacy in patients with advanced MTC [33] MS0019266 Exhibited anticancer activities in Drosophila expressing oncogenic MEN2B and increased the viability of the Drosophila larvae and the number of organisms reaching the pupal and adult stages [35] Indomethacin Enhanced hAPC-induced eye defects in the fly [40] Oxazoles, thiazoles, thiazolidinedione Exhibited potent inhibitory effects on b-catenin-responsive transcription in Drosophila [42] DAPT, Cpd E, thapsigargin, cyclopiazonic acid…”